Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation
Mark Rusznak, Christopher M. Thomas, Jian Zhang, Shinji Toki, Weisong Zhou, Masako Abney, Danielle M. Yanda, Allison E. Norlander, Craig A. Hodges, Dawn C. Newcomb, Mark H. Kaplan, R. Stokes Peebles Jr., Daniel P. Cook
Mark Rusznak, Christopher M. Thomas, Jian Zhang, Shinji Toki, Weisong Zhou, Masako Abney, Danielle M. Yanda, Allison E. Norlander, Craig A. Hodges, Dawn C. Newcomb, Mark H. Kaplan, R. Stokes Peebles Jr., Daniel P. Cook
View: Text | PDF
Research Article Immunology Inflammation Pulmonology

CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation

  • Text
  • PDF
Abstract

Type 2 inflammatory diseases, including asthma, sinusitis, and allergic bronchopulmonary aspergillosis, are common in cystic fibrosis (CF). CD4+ Th2 cells promote these diseases through secretion of IL-4, IL-5, and IL-13. Whether the CF transmembrane conductance regulator (CFTR), the mutated protein in CF, has a direct effect on Th2 development is unknown. Using murine models of CFTR deficiency and human CD4+ T cells, we show that CD4+ T cells expressed Cftr transcript and CFTR protein following activation. Loss of T cell CFTR expression increased Th2 cytokine production compared with control cells. Mice with CFTR-deficient T cells developed increased allergic airway disease to Alternaria alternata extract compared with control mice. Culture of CFTR-deficient Th2 cells demonstrated increased IL-4Rα expression and increased sensitivity to IL-4 with greater induction of GATA3 and IL-13 compared with control Th2 cell cultures. The CFTR potentiator ivacaftor reduced allergic inflammation and type 2 cytokine secretion in bronchoalveolar lavage of humanized CFTR mice following Alternaria alternata extract challenge and decreased Th2 development in human T cell culture. These data support a direct role of CFTR in regulating T cell sensitivity to IL-4 and demonstrate a potential CFTR-specific therapeutic strategy for Th2 cell–mediated allergic disease.

Authors

Mark Rusznak, Christopher M. Thomas, Jian Zhang, Shinji Toki, Weisong Zhou, Masako Abney, Danielle M. Yanda, Allison E. Norlander, Craig A. Hodges, Dawn C. Newcomb, Mark H. Kaplan, R. Stokes Peebles Jr., Daniel P. Cook

×

Figure 7

CFTR potentiation decreases Th2 GATA3 expression and IL-13 production.

Options: View larger image (or click on image) Download as PowerPoint
CFTR potentiation decreases Th2 GATA3 expression and IL-13 production.
(...
(A) Schematic diagram detailing the isolation and Th2 polarization of naive human CD4+ T cells used for flow cytometry and cytokine analysis. (B) Viability of ivacaftor (IVA) or DMSO (control) cultured human Th2 cells at 7 days. (C) Representative flow cytometry histogram showing the median fluorescence intensity (MFI) of GATA3 at 7 days for DMSO- and IVA-treated Th2 cells. (D) The quantified MFI of GATA3 in DMSO- and IVA-treated Th2 cells at 72 hours (n = 6 paired human samples). (E) Representative flow cytometry histogram showing the median fluorescence intensity (MFI) of IL-13 at 7 days for DMSO- and IVA-treated Th2 cells. (F) The quantified MFI of IL-13 in DMSO- and IVA-treated Th2 cells at 72 hours (n = 6 paired human samples). (G) IL-13 by ELISA in cellular supernatant from cultured DMSO- and IVA-treated Th2 cells. Statistical analysis in B, D, F, and G was performed using paired Student’s t test. *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts